Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0ET2T
|
|||
| Former ID |
DNCL003568
|
|||
| Drug Name |
GSK2586881
|
|||
| Synonyms |
GSK-2586881
Click to Show/Hide
|
|||
| Indication | Acute lung injury [ICD-11: NB32.3; ICD-10: S27.3; ICD-9: 518] | Phase 2 | [1] | |
| Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Phase 1 | [2] | ||
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme 2 (ACE2) | Target Info | Modulator | [3] |
| KEGG Pathway | Renin-angiotensin system | |||
| Protein digestion and absorption | ||||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01597635) The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.